Galectin Therapeutics IncNASDAQ:GALT
- LAST PRICE3.1500
- TODAY'S CHANGE (%)0.0100 (0.3185%)
- Bid / Lots3.1200/ 1
- Ask / Lots3.1500/ 1
- Open / Previous Close3.1800 / 3.1400
- Day Range
- 52 Week Range
- Volume17,113
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GALT |
|---|---|---|
| 09:32 ET | 3802 | 3.15 |
| 09:34 ET | 13053 | 3.15 |
May 15, 2024
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update, from 8:00AM ET on Wednesday May 15, 2024 by Dow Jones
8:00AM ET on Wednesday May 15, 2024 by Dow Jones*DJ Galectin Therapeutics 4Q Loss/Shr 19c >GALT, from 8:00AM ET on Wednesday May 15, 2024 by Dow Jones
8:00AM ET on Wednesday May 15, 2024 by Dow Jones
May 13, 2024
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference, from 8:00AM ET on Monday May 13, 2024 by Dow Jones
8:00AM ET on Monday May 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Galectin Therapeutics Inc | 194.4M | -4.3x | --- |
Kodiak Sciences Inc | 196.5M | -0.8x | --- |
Omeros Corp | 191.8M | -1.2x | --- |
Elevation Oncology Inc | 197.2M | -3.5x | --- |
Trevi Therapeutics Inc | 200.0M | -8.2x | --- |
Atossa Therapeutics Inc | 201.7M | -6.6x | --- |
Company Information
Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company's lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the United States Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
Contact Information
- Headquarters
- SUITE 240 4960 PEACHTREE INDUSTRIAL BOULEVARDNORCROSS, GA, United States 30071
- Phone
- 678-620-3186
- Fax
- 770-864-1327
Executives
- Independent Chairman of the Board
- Richard Uihlein
- President, Chief Executive Officer, Director
- Joel Lewis
- Chief Financial Officer
- Jack Callicutt
- Chief Medical Officer
- Pol Boudes
- Director
- Benjamin Carson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $194.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 61.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.67 |
EPS | $-0.74 |
Book Value | $-0.97 |
P/E Ratio | -4.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
